<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075318</url>
  </required_header>
  <id_info>
    <org_study_id>UB-312-101</org_study_id>
    <nct_id>NCT04075318</nct_id>
  </id_info>
  <brief_title>Study of UB-312 in Healthy Participants and Parkinson's Disease Patients</brief_title>
  <official_title>A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UBITh® PD Immunotherapeutic Vaccine (UB-312) in Healthy Participants and Participants With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Neuroscience Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre for Human Drug Research, Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Worldwide Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>United Neuroscience Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 44-week, randomized, placebo-controlled, double-blind, single-center, phase 1
      clinical trial consisting of a dose-escalation Part A study in healthy participants, followed
      by a Part B in participants with Parkinson's disease with a selected dose from Part A.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human Phase 1 study to determine the safety, tolerability, and
      immunogenicity of UB-312 in healthy participants and in participants with Parkinson's disease
      (PD). UB-312 is a UBITh®-enhanced synthetic peptide-based vaccine and may provide an active
      immunotherapy option for treating synucleinopathies including the most prevalent form, PD.

      The study consists of two parts. Part A of the study with healthy participants will consist
      of dose escalation and cohort staggering for up to seven planned dose levels or placebo. The
      dose for Part B, a cohort with PD participants will be based on safety, tolerability and
      immunogenicity. All eligible participants will be enrolled in a 44-week study consisting of
      20 weeks of treatment and 24 weeks of follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>44 weeks</time_frame>
    <description>Number of AEs will be assessed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity of UB-312 as determined by anti-aSyn antibodies in blood and CSF</measure>
    <time_frame>Weeks 1, 2, 5, 6, 9, 13, 14, 17 and 21</time_frame>
    <description>Immunogenicity will be measured by change from baseline of blood and CSF anti-aSyn antibody titers.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Parkinsonism</condition>
  <arm_group>
    <arm_group_label>UB-312 40 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 ug by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 100 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 100 ug by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 40/300 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 ug at Week 1 and 300 ug at Weeks 5 and 13 by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 300 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 300 ug by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 40/1000 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 40 ug at Week 1 and 1000 ug at Weeks 5 and 13 by intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 1000 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 1000 ug by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UB-312 2000 ug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UB-312 2000 ug by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo by intramuscular injection at Weeks 1, 5 and 13</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>UB-312</intervention_name>
    <description>A synthetic peptide-based vaccine</description>
    <arm_group_label>UB-312 100 ug</arm_group_label>
    <arm_group_label>UB-312 1000 ug</arm_group_label>
    <arm_group_label>UB-312 2000 ug</arm_group_label>
    <arm_group_label>UB-312 300 ug</arm_group_label>
    <arm_group_label>UB-312 40 ug</arm_group_label>
    <arm_group_label>UB-312 40/1000 ug</arm_group_label>
    <arm_group_label>UB-312 40/300 ug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 40 to 85 years old, inclusive at screening

          -  Expected to be able to undergo all study procedures

          -  Other inclusion criteria apply

        For Part B only:

          -  A diagnosis of PD, confirmed by a neurologist

          -  Hoehn &amp;Yahr Stage ≤ III at Screening

          -  Stable treatment of permitted antiparkinsonian medications from 30 days prior to first
             study drug administration or 60 days for MAO-B inhibitors, and expected to remain
             stable throughout the study

        Exclusion Criteria:

          -  Clinically significant abnormalities, as judged by the investigator

          -  History of medical, neurological or psychiatric conditions

          -  Active or chronic infection as judged by the investigator, for positive human
             immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis B virus (HBV)

          -  History or evidence of an autoimmune disorder

          -  History of anergy.

          -  Participated/participating in any clinical trial with monoclonal antibodies or
             vaccines directed at aSyn

          -  Other exclusion criteria apply

        For Part B only:

          -  Other known or suspected cause of Parkinsonism other than idiopathic PD

          -  History or evidence at Screening of PD-related freezing episodes, falls, or
             orthostatic hypotension

          -  Dopamine transporter single-photon emission computerized tomography scan (DaTscan)
             inconsistent with dopamine transporter deficit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trial Manager</last_name>
    <phone>+353 1 524 0397</phone>
    <email>ub312101@unitedneuroscience.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Geert Jan Groeneveld, MD, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Wang CY, Walfield AM. Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine. 2005 Mar 18;23(17-18):2049-56.</citation>
    <PMID>15755569</PMID>
  </reference>
  <reference>
    <citation>Wang CY, Finstad CL, Walfield AM, Sia C, Sokoll KK, Chang TY, Fang XD, Hung CH, Hutter-Paier B, Windisch M. Site-specific UBITh amyloid-beta vaccine for immunotherapy of Alzheimer's disease. Vaccine. 2007 Apr 20;25(16):3041-52. Epub 2007 Jan 19.</citation>
    <PMID>17287052</PMID>
  </reference>
  <reference>
    <citation>Wang CY, Wang PN, Chiu MJ, Finstad CL, Lin F, Lynn S, Tai YH, De Fang X, Zhao K, Hung CH, Tseng Y, Peng WJ, Wang J, Yu CC, Kuo BS, Frohna PA. UB-311, a novel UBITh(®) amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimers Dement (N Y). 2017 Apr 14;3(2):262-272. doi: 10.1016/j.trci.2017.03.005. eCollection 2017 Jun.</citation>
    <PMID>29067332</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>September 2, 2019</last_update_submitted>
  <last_update_submitted_qc>September 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Parkinsonian Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

